EFFECT OF DIENOGEST AND MEDROXYPROGESTERONE ACETATE (MPA) ON QUALITY OF LIFE IN ENDOMETRIOSIS: A COMPARATIVE STUDY

Dr. Amiya*, Dr. Jyoti Kaushal and Dr. Savita Rani Singhal

ABSTRACT

Introduction: Endometriosis is common in reproductive women usually between 15 to 49 years age characterized by clinical symptoms like dysmenorrhea, chronic pelvic pain, dyspareunia, dyschezia, irregular uterine bleeding and infertility which can severely affect a woman's quality of life (QOL). This study was done to observe improvement in quality of life after treatment with dienogest versus medroxyprogesterone acetate (MPA) in women with endometriosis. Materials & Methods: A prospective, randomized, comparative clinical study was conducted on 60 patients and they were randomly divided in two groups of 30 each to receive either Dienogest 2 mg OD (Group A) or Medroxyprogesterone acetate 10 mg BD (Group B) orally for 12 weeks. Quality of life assessment was done using Endometriosis health profile-30 (EHP-30) Questionnaire. Results: At the end of 12 weeks, there was reduction in the scores of all the domains of QOL with both the drugs i.e. pain domain, control & powerlessness domain, emotion domain, social support domain and self-image domain in dienogest group (79.19%, 74.82%, 77.82%, 68.99% and 53.96%) and MPA group (61.86%, 62.58%, 61.30%, 54.48% and 19.03%) respectively as compared to baseline values. On intergroup analysis, dienogest showed statistically significant better response than MPA in reduction of pain & emotional domain (p=0.004 & p=0.012 respectively). Conclusion: Although there was a definite improvement in QOL with both types of treatment in women with endometriosis but on comparing both the groups, dienogest showed more improvement in QOL than MPA especially in pain & emotional domain.

Keywords: Dienogest, medroxyprogesterone acetate, endometriosis, quality of life, endometriosis health profile-30, progestin.